SCHEDULE 13D/A: New Enterprise Associates Entities Reduce Stake in Verona Pharma plc Below 5% Threshold
Schedule 13D Amendment
New Enterprise Associates and its affiliated entities have reduced their beneficial ownership in Verona Pharma plc to below the 5% reporting threshold through pro-rata distributions of shares.
Summary
- Growth Equity Opportunities 15, LLC (GEO 15) distributed ADSs representing 2,620,720 Ordinary Shares to New Enterprise Associates 15, L.P. (NEA 15) on January 16, 2025.
- NEA 15 subsequently made a pro-rata distribution of these shares to its general partner and limited partners for no consideration.
- Growth Equity Opportunities 17, LLC (GEO 17) distributed ADSs representing 9,379,280 Ordinary Shares to New Enterprise Associates 17, L.P. (NEA 17) on January 16, 2025.
- NEA 17 subsequently made a pro-rata distribution of these shares to its general partner and limited partners for no consideration.
- Following these distributions, each of the Reporting Persons, including various New Enterprise Associates entities and their managing partners, ceased to beneficially own five percent (5%) or more of Verona Pharma plc's Ordinary Shares.
- The beneficial ownership for the primary group of reporting persons (e.g., Growth Equity Opportunities 17, LLC, NEA 17, NEA 15, and certain managers) is now 32,678,025 Ordinary Shares, representing 4.99% of the class.
- Other individual managers (Ali Behbahani, Carmen Chang, Edward T. Mathers, Paul Walker, Rick Yang) report beneficial ownership of approximately 25,541,000 shares, representing 3.90% of the class.
- The percentage of outstanding Ordinary Shares was calculated based on 654,649,358 Ordinary Shares reported by Verona Pharma plc as outstanding as of October 28, 2024, in its Form 10-Q filed on November 4, 2024.
Sentiment
Score: 5
Explanation: The document is a factual report of a change in beneficial ownership, specifically a reduction below a reporting threshold due to internal fund distributions. It does not contain information that is inherently positive or negative for the issuer's operations or financial health.
Future Outlook
This document does not contain any forward-looking statements or guidance regarding Verona Pharma plc's future outlook.
Industry Context
This filing is a routine disclosure of a change in beneficial ownership by a significant institutional investor in a publicly traded biotechnology company. It reflects a portfolio management decision by the investment funds rather than a direct commentary on broader industry trends or the specific performance of the pharmaceutical sector.
Stakeholder Impact
- Shareholders: The reduction of a significant institutional investor's stake below the 5% threshold may lead to reduced institutional oversight or influence, and could be interpreted by some as a change in investment conviction, though the filing states the distributions were for no consideration and pro-rata.
Key Dates
| Date | Description |
|---|---|
| 2024-02-29 | Date of Power of Attorney for signing SEC filings. |
| 2024-10-28 | Date as of which Verona Pharma plc reported 654,649,358 Ordinary Shares outstanding in its Form 10-Q. |
| 2024-11-04 | Date Verona Pharma plc filed its Form 10-Q with the SEC. |
| 2025-01-16 | Date of event which required the filing of this statement; distributions of ADSs by GEO 15 and GEO 17 occurred, leading to reporting persons ceasing to beneficially own 5% or more of the Issuer's Ordinary Shares. |
| 2025-01-21 | Date of execution of the Agreement regarding joint Schedule 13D filing and the signing date of this Amendment No. 4 to Schedule 13D. |
Keywords
Verona Pharma plc, New Enterprise Associates, SEC filing, Schedule 13D, Beneficial Ownership, Share Distribution, Institutional Investor, Biotechnology, Pharmaceuticals, Investment Fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.